Skip to main content

NextCure, Inc.

corporate_fare Company Profile

NextCure, Inc.

NXTC·NASDAQ·Life Sciences·CIK 0001661059

We are a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer patients who do not respond to or experience disease progression on current therapies. We achieve this through targeted therapies, including antibody-drug conjugates (ADCs). An ADC combines a monoclonal antibody with a cytotoxic drug using a chemical linker. Our focus leverages our understanding of biological pathways, biomarkers, cell interactions within the tumor microenvironment, and their role in biological responses. Our product candidate, SIM0505, is a novel ADC candidate developed by Simcere Zaiming Pharmaceutical Co., Ltd. (Zaiming). We hold an exclusive, worldwide license (excluding China, Hong Kong, Macau, and Taiwan, referred to as the "Zaiming Territory") to develop, manufacture, and commercialize Zaiming's clinical-stage ADC candidate, SIM0505, and related compounds (the "Zaiming Products"). We also have a non-exclusive, worldwide license (excluding the Zaiming Territory) to use Zaiming's ADC platform technology to develop ADCs based on our proprietary antibodies for an additional novel target (the "NextCure Products"). Zaiming retains exclusive rights for the Zaiming Products and any NextCure Products in the Zaiming Territory. SIM0505 targets cadherin-6 (CDH6), an anti-tumor target, using a unique binding epitope designed for increased tumor binding. It incorporates Zaiming's proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity and fast systemic clearance to expand the therapeutic window. Preclinical studies have shown robust anti-tumor activity across multiple solid tumor models and a promising safety profile in toxicology models. Zaiming is currently conducting Phase 1 dose escalation studies in China for SIM0505 to treat solid tumors, including ovarian, endometrial, non-small cell lung, and renal cancers. In December 2024, Zaiming received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) for a Phase 1 clinical trial for treating multiple cancers.

NextCure, Inc. (NASDAQ:NXTC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for NXTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 16 rated 8 or above. Recent SEC coverage for NXTC spans 8-K, 10-Q, S-4/A, 425.

Recent high-impact activity:

  • NextCure Sets CVR Record Date of Dec 8 and Distribution Date of Dec 14 for Avere Merger
  • NextCure Receives Nasdaq Equity Deficiency Notice; January 4, 2027 Cure Deadline Set
  • NextCure 10-Q: $8.7M Cash, Going Concern Warning and Nasdaq Equity Deficiency Ahead of Dec 9 Merger Vote
  • NextCure Posts $6.8M Q3 Loss With $8.7M Cash Ahead of December 9 Merger Vote
  • Avere Merger Financing Grows to ~$820M With New $500M Placement

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$55.84M
Diluted EPS
-$19.65
Op. Cash Flow
-$49.61M
Operating Income
-$57.62M
Cash & Equivalents
$25.98M
Debt / Equity
0.00×
Shares Outstanding
3.51M sh
Source: 10-K · filed 2026-03-05 · accession 0001104659-26-024137

Short Interest & Short Volume

2.97 days to cover

FINRA reported short interest of 184,029 shares in NXTC as of the October 30, 2026 settlement, a 16.7% decrease from the prior period — about 3.0 days to cover at its recent average daily volume. On November 20, 2026, 11.9% of NXTC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)184,029 shares as of October 30, 2026
Change vs prior period▼ 16.7%
Days to cover2.97 at avg daily volume of 61,907
Daily short volume (FINRA facilities)11.9% of 14,413 shares on November 20, 2026
5-day average short volume32.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with N →
$6.17 -4.34% today
52-week range · as of 2026-11-20 $1.55 – $15.74
Market cap
$29.53M
Volume
30.9K (0.5× avg)
3-mo avg 57.4K
Live data · 2026-11-21 16:59 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NXTC - Latest Insights

NXTC
Nov 20, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.45
Real-time Price: $6.17 info
Change: -$0.280 (-4%) info
Market Cap: $29.535M info
NXTC
Nov 20, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.08
Real-time Price: $6.17 info
Change: -$0.910 (-13%) info
Market Cap: $29.535M info
NXTC
Nov 10, 2026, 4:25 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.78
Real-time Price: $6.17 info
Change: +$0.390 (+7%) info
Market Cap: $29.535M info
NXTC
Nov 10, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.17 info
Change: +$0.390 (+7%) info
Market Cap: $29.535M info
NXTC
Nov 10, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $5.78
Real-time Price: $6.17 info
Change: +$0.390 (+7%) info
Market Cap: $29.535M info
NXTC
Oct 30, 2026, 8:39 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $6.31
Real-time Price: $6.17 info
Change: -$0.140 (-2%) info
Market Cap: $29.535M info
NXTC
Sep 30, 2026, 7:36 PM EDT
Filing Type: S-4/A
Importance Score:
9
Price at Filing: $5.01
Real-time Price: $6.17 info
Change: +$1.16 (+23%) info
Market Cap: $29.535M info
NXTC
Sep 25, 2026, 4:12 PM EDT
Filing Type: 425
Importance Score:
8
Price at Filing: $5.08
Real-time Price: $6.17 info
Change: +$1.09 (+21%) info
Market Cap: $29.535M info
NXTC
Sep 25, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.08
Real-time Price: $6.17 info
Change: +$1.09 (+21%) info
Market Cap: $29.535M info
NXTC
Aug 18, 2026, 5:29 PM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $6.70
Real-time Price: $6.17 info
Change: -$0.530 (-8%) info
Market Cap: $29.535M info
NXTC
Aug 10, 2026, 4:01 PM EDT
Filing Type: 425
Importance Score:
9
Price at Filing: $6.90
Real-time Price: $6.17 info
Change: -$0.730 (-11%) info
Market Cap: $29.535M info
NXTC
Aug 10, 2026, 9:55 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $6.77
Real-time Price: $6.17 info
Change: -$0.600 (-9%) info
Market Cap: $29.535M info
NXTC
Aug 04, 2026, 7:30 AM EDT
Filing Type: 425
Importance Score:
8
Price at Filing: $4.72
Real-time Price: $6.17 info
Change: +$1.45 (+31%) info
Market Cap: $29.535M info
NXTC
Aug 03, 2026, 5:53 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $6.17 info
Change: +$2.00 (+48%) info
Market Cap: $29.535M info
NXTC
Jul 16, 2026, 5:28 PM EDT
Filing Type: 425
Importance Score:
8
Price at Filing: $6.01
Real-time Price: $6.17 info
Change: +$0.160 (+3%) info
Market Cap: $29.535M info
NXTC
Jul 14, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $8.08
Real-time Price: $6.17 info
Change: -$1.91 (-24%) info
Market Cap: $29.535M info
NXTC
Jul 14, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.90
Real-time Price: $6.17 info
Change: +$3.27 (+113%) info
Market Cap: $29.535M info
NXTC
Jun 01, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.20
Real-time Price: $6.17 info
Change: -$0.030 (-0.48%) info
Market Cap: $29.535M info
NXTC
Jun 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.20
Real-time Price: $6.17 info
Change: -$0.030 (-0.48%) info
Market Cap: $29.535M info
NXTC
May 07, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.18
Real-time Price: $6.17 info
Change: -$4.01 (-39%) info
Market Cap: $29.535M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets